Probiotic Y7 cocktail to help with early Parkinson’s symptoms
Official title: Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease - Use Preclinical Human Trials to Confirm the Impact of the Optimal "Probiotic Y7, Tryptophan and Branched-chain Amino Acid" Cocktail Formula on Early Stage Parkinson's Disease Patient
Run by Taipei Medical University · NCT07619560 · Data updated 2026-11-12
A 12-week randomized trial will test whether a probiotic Y7 cocktail helps people with early Parkinson’s disease by possibly improving motor, thinking, and everyday symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 85 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Taipei Medical University Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | May 20, 2025 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT07619560 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 30–85 with early-stage Parkinson’s (stage 1–3) who respond to PD medications and have MRI-confirmed striatal degeneration without major illnesses.
✕Probably not a fit
Patients who do not experience a response to the probiotic cocktail or have contraindications may not see benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial uses preclinical human work to guide a two-arm randomized design, comparing the Y7 probiotic cocktail to placebo in adults with early-stage Parkinson’s disease. It will recruit about 120 participants (Hoehn and Yahr stages 1–3) and measure motor function, cognition, and non-motor symptoms as outcomes. The study will collect clinical data, biomarkers, and questionnaires to build a personalized prognosis model while evaluating any potential delay in disease progression. If results are favorable, the program may advance toward commercial development. The sponsor is Taipei Medical University, with participating hospitals in Taipei.
Why it matters
Potential benefit: If successful, the probiotic cocktail could slow progression of motor and non-motor symptoms in early Parkinson’s disease.
How similar studies have gone: Prior similar probiotic approaches in neurological conditions have shown mixed results; this study builds on preclinical human data to test a targeted Y7 formulation in PD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Subject Inclusion Criteria: 1. Age between 30-85 years old. 2. Diagnosed with early-stage Parkinson's disease (Hoehn and Yahr scale stage 1-3). 3. Brain MRI confirms striatal degeneration in the basal ganglia region, with no history of stroke. 4. Responds to Parkinson's disease-related medications (e.g., Levodopa). 5. Free of any major or acute illnesses. 6. Able to comply with the 12 weeks intervention and required assessments for the study. Exclusion Criteria: 1. Unable to complete interviews or has mobility issues. 2. Presence of major or acute illness before or during the study. 3. Co-existing intestinal co-infections, such as CDI, E. coli, Salmonella, Shigella, Campylobacter, plague, or cytomegalovirus. 4. Allergic to the intervention product. 5. Pregnant or breastfeeding women.
Where it's running
-
Taipei Medical University Hospital
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Hui Yu Huang, PhD
- Email: maggieh323@tmu.edu.tw
- Phone: 02-27361661
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut-brain in PD Consortium: understanding gut influences in Parkinson's and prodromal stages
This study tests how the gut and brain communicate in people with Parkinson's, those without PD, and those at risk, to see if gut factors relate to disease onset and progression.
-
Parkinson’s Risk in Gaucher Disease Type 1
This study tests how Parkinson’s risk relates to GBA1-related Gaucher disease in adults over 40, by collecting detailed clinical data and samples for future research.
-
Barley and kefir to support gut health in active adults
This study tests whether a daily barley and kefir meal for four weeks can change gut microbiota in physically active adults and whether those changes relate to certain metabolites in blood and urine.
-
Can the Ronnie Gardiner Method improve thinking and daily function in people with Parkinson’s
In this 10-week program, adults with Parkinson’s disease will try the Ronnie Gardiner Method to see if it helps thinking, talking, movement, balance, and quality of life.
-
Overnight Temperature Regulation to Test Gut Health, Inflammation, and Circadian Rhythms
This study tests whether two weeks of using the Eight Sleep Pod at night can improve gut bacteria balance, lower inflammation, and strengthen daily temperature and blood pressure rhythms in postmenopausal women and age-matched men with poor sleep.
-
Probiotics to Prevent Pneumonia in Critically Ill Kids in the PICU
We’re testing whether giving probiotics to critically ill children on a ventilator helps prevent ventilator-associated pneumonia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.